Mangiferin modulation of metabolism and metabolic syndrome

BioFactors

Volumn 42, Issue 5, 2016, Pages 492-503

  Fomenko, Ekaterina Vladimirovna ^a   Chi, Yuling ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

hyperglycemia; hyperlipidemia; inflammation; Mangiferin; metabolism

Indexed keywords

CARBOHYDRATE; LIPID; MANGIFERIN; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; PLANT EXTRACT; XANTHONE DERIVATIVE;

CARBOHYDRATE METABOLISM; CELL PROTECTION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; LIPID METABOLISM; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; ANIMAL; CARDIOVASCULAR DISEASES; DRUG EFFECTS; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; METABOLIC SYNDROME X; PLANT EXTRACTS; XANTHONES;

EID: 84992391900     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.1309     Document Type: Review

References (122)

1. Alberti, K. G., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J. C., James, W. P., Loria, C. M., and Smith, S. C. Jr., E. International Diabetes Federation Task Force on, Prevention, L., Hational Heart, I., Blood, a. American Heart, F. World Heart, S. International Atherosclerosis, O. (2009) International Association for the Study of Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640–1645.
2. Danaei, G., Finucane, M. M., Lu, Y., Singh, G. M., Cowan, M. J., et al. (2011) Global burden of metabolic risk factors of chronic diseases collaborating national, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378, 31–40.
3. Flegal, K. M., Carroll, M. D., Kit, B. K., and Ogden, C. L. (2012) Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA 307, 491–497.
4. Chung, A., Backholer, K., Wong, E., Palermo, C., Keating, C., et al. (2016) Trends in child and adolescent obesity prevalence in economically advanced countries according to socioeconomic position: a systematic review. Obes. Rev. 17, 276–295.
5. Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., et al. (2016) Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association. Circulation 133, e38–e360.
6. Lam, D. W., and LeRoith D. (2000) In Endotext (De Groot, L. J., Beck-Peccoz, P., Chrousos, G., Dungan, K., Grossman, A., et al., eds.) South Dartmouth (MA).
7. Grabowski, H. (2004) Are the economics of pharmaceutical research and development changing? Productivity, patents and political pressures. Pharmacoeconomics 22, 15–24.
8. Vernon, J. A. (2005) Examining the link between price regulation and pharmaceutical R&D investment. Health Econ. 14, 1–16.
9. Tobinick, E. L. (2009) The value of drug repositioning in the current pharmaceutical market. Drug News Perspect. 22, 119–125.
10. Bach, R. G., Brooks, M. M., Lombardero, M., Genuth, S., Donner, T. W., et al. (2013) Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation 128, 785–794.
11. Maksimov, M. L., Svistunov, A. A., Tarasov, V. V., Chubarev, V. N., Avila-Rodriguez, M., et al. (2016) Approaches for the development of drugs for treatment of obesity and metabolic syndrome. Curr. Pharm. Des. 22, 895–903.
12. Butler, M. S. (2005) Natural products to drugs: natural product derived compounds in clinical trials. Nat. Prod. Rep. 22, 162–195.
13. Newman, D. J., and Cragg, G. M. (2007) Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 70, 461–477.
14. Lu, J. M., Wang, Y. F., Yan, H. L., Lin, P., Gu, W., and Yu, J. (2016) Antidiabetic effect of total saponins from Polygonatum kingianum in streptozotocin-induced daibetic rats. J. Ethnopharmacol. 179, 291–300.
15. Zhang, X. T., Yu, C. J., Liu, J. W., Zhang, Y. P., Zhang, C., et al. (2015) Qizhi Jiangtang Jiaonang improves insulin signaling and reduces inflammatory cytokine secretion and reactive oxygen species formation in insulin resistant HepG2 cells. Evid-Based Compl. Alt. Med. 2015, 518639.
16. Wu, T., Sun, J., Kagota, S., Maruyama, K., Wakuda, H., and Shinozuka, K. (2016) Panax notoginseng saponins ameliorate impaired arterial vasodilation in SHRSP.Z-Lepr/lzmDmcr rats with metabolic syndrome. Clin. Exp. Pharmacol. Physiol. 43, 459–467.
17. Sanchez, G. M., Re, L., Giuliani, A., Nunez-Selles, A. J., Davison, G. P., and Leon-Fernandez, O. S. (2000) Protective effects of Mangifera indica L. extract, mangiferin and selected antioxidants against TPA-induced biomolecules oxidation and peritoneal macrophage activation in mice. Pharmacol. Res. 42, 565–573.
18. Barreto, J. C., Trevisan, M. T., Hull, W. E., Erben, G., de Brito, E. S., et al. (2008) Characterization and quantitation of polyphenolic compounds in bark, kernel, leaves, and peel of mango (Mangifera indica L.). J. Agric. Food Chem. 56, 5599–5610.
19. Han, D., Chen, C., Zhang, C., Zhang, Y., and Tang, X. (2010) Determination of mangiferin in rat plasma by liquid–liquid extraction with UPLC–MS/MS. J. Pharm. Biomed. Anal. 51, 260–263.
20. Hou, S. Y., Wang, F., Li, Y. M., Li, Y., Wang, M. Q., et al. (2012) Pharmacokinetic study of mangiferin in human plasma after oral administration. Food Chem. 132, 289–294.
21. Ma, H., Chen, H., Sun, L., Tong, L., and Zhang, T. (2014) Improving permeability and oral absorption of mangiferin by phospholipid complexation. Fitoterapia 93, 54–61.
22. Benard, O., and Chi, Y. (2015) Medicinal properties of mangiferin, structural features, derivative synthesis, pharmacokinetics and biological activities. Mini Rev. Med. Chem. 15, 582–594.
23. 2+-citrate. Eur. J. Pharmacol. 513, 47–55.
24. Leiro, J. M., Alvarez, E., Arranz, J. A., Siso, I. G., and Orallo, F. (2003) In vitro effects of mangiferin on superoxide concentrations and expression of the inducible nitric oxide synthase, tumour necrosis factor-alpha and transforming growth factor-beta genes. Biochem. Pharmacol. 65, 1361–1371.
25. Rajendran, P., Ekambaram, G., and Sakthisekaran, D. (2008) Cytoprotective effect of mangiferin on benzo(a)pyrene-induced lung carcinogenesis in Swiss albino mice. Basic Clin. Pharmacol. Toxicol. 103, 137–142.
26. Yoshikawa, M., Shimoda, H., Nishida, N., Takada, M., and Matsuda, H. (2002) Salacia reticulata and its polyphenolic constituents with lipase inhibitory and lipolytic activities have mild antiobesity effects in rats. J. Nutr. 132, 1819–1824.
27. Kishino, E., Ito, T., Fujita, K., and Kiuchi, Y. (2006) A mixture of the Salacia reticulata (Kotala himbutu) aqueous extract and cyclodextrin reduces the accumulation of visceral fat mass in mice and rats with high-fat diet-induced obesity. J. Nutr. 136, 433–439.
28. Im, R., Mano, H., Nakatani, S., Shimizu, J., and Wada, M. (2008) Aqueous extract of Kotahla Himbutu (Salacia reticulata) stems promotes oxygen consumption and suppresses body fat accumulation in mice. J. Health Sci. 54, 645–653.
29. Shimada, T., Nagai, E., Harasawa, Y., Akase, T., Aburada, T. et al. (2010) Metabolic disease prevention and suppression of fat accumulation by Salacia reticulata. J. Nat. Med. Tokyo 64, 266–274.
30. Shimada, T., Akase, T., Kosugi, M., and Aburada, M. (2011) Preventive effect of boiogito on metabolic disorders in the TSOD mouse, a model of spontaneous obese type ii diabetes mellitus. Evid-Based Compl. Alt. Med. 2011, 1–8.
31. Ikarashi, N., Toda, T., Okaniwa, T., Ito, K., Ochiai, W., and Sugiyama, K. (2011) Anti-obesity and anti-diabetic effects of acacia polyphenol in obese diabetic KKAy mice fed high-fat diet. Evid-Based Compl. Alt. Med. 2011, 1–10.
32. Ross, S. M. (2011) African mango (IGOB131). A proprietary seed extract of Irvingia gabonensis is found to be effective in reducing body weight and improving metabolic parameters in overweight humans. Holist. Nurs. Pract. 25, 215–217.
33. Guo, F., Huang, C., Liao, X., Wang, Y., He, Y., Feng, R., et al. (2011) Beneficial effects of mangiferin on hyperlipidemia in high-fat-fed hamsters. Mol. Nutr. Food Res. 55, 1809–1818.
34. Apontes, P., Liu, Z. B., Su, K., Benard, O., Youn, D. Y., et al. (2014) Mangiferin stimulates carbohydrate oxidation and protects against metabolic disorders induced by high-fat diets. Diabetes 63, 3626–3636.
35. Han, J., Yi, J., Liang, F. Y., Jiang, B., Xiao, Y., et al. (2015) X-3, a mangiferin derivative, stimulates AMP-activated protein kinase and reduces hyperglycemia and obesity in db/db mice. Mol. Cell Endocrinol. 405, 63–73.
36. Shimada, T., Nagai, E., Harasawa, Y., Watanabe, M., Negishi, K., et al. (2011) Salacia reticulata inhibits differentiation of 3T3-L1 adipocytes. J. Ethnopharmacol. 136, 67–74.
37. Niu, Y., Li, S., Na, L., Feng, R., and Liu, L. (2012) Mangiferin decreases plasma free fatty acids through promoting its catabolism in liver by activation of AMPK. PloS One 7, e30782.
38. Lim, J., Liu, Z., Apontes, P., Feng, D., and Pessin, J. E. (2014) Dual mode action of mangiferin in mouse liver under high fat diet. PloS One 9, e90137.
39. Foufelle, F., and Ferre, P. (2002) New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem. J. 366, 377–391.
40. Horton, J. D., Goldstein, J. L., and Brown, M. S. (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Investig. 109, 1125–1131.
41. Horton, J. D., Shah, N. A., Warrington, J. A., Anderson, N. N., Park, S. W., et al. (2003) Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. USA 100, 12027–12032.
42. Choi, C. S., Savage, D. B., Kulkarni, A., Yu, X. X., Liu, Z. X., et al. (2007) Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J. Biol. Chem. 282, 22678–22688.
43. Stahl, A. (2004) A current review of fatty acid transport proteins (SLC27). Pflugers Arch. 447, 722–727.
44. Coburn, C. T., Hajri, T., Ibrahimi, A., and Abumrad, N. A. (2001) Role of CD36 in membrane transport and utilization of long-chain fatty acids by different tissues. J. Mol. Neurosci. 16, 117–121 (discussion 151–117).
45. Rakhshandehroo, M., Knoch, B., Muller, M., and Kersten, S. (2010) Peroxisome proliferator-activated receptor alpha target genes. PPAR Res. 2010, 1–10.
46. Muruganandan, S., Srinivasan, K., Gupta, S., Gupta, P. K., and Lal, J. (2005) Effect of mangiferin on hyperglycemia and atherogenicity in streptozotocin diabetic rats. J. Ethnopharmacol. 97, 497–501.
47. Xing, X., Li, D., Chen, D., Zhou, L., Chonan, R., et al. (2014) Mangiferin treatment inhibits hepatic expression of acyl-coenzyme A:diacylglycerol acyltransferase-2 in fructose-fed spontaneously hypertensive rats: a link to amelioration of fatty liver. Toxicol. Appl. Pharmacol. 280, 207–215.
48. Zhou, L., Pan, Y., Chonan, R., Batey, R., Rong, X., et al. (2016) Mitigation of insulin resistance by mangiferin in a rat model of fructose-induced metabolic syndrome is associated with modulation of CD36 redistribution in the skeletal muscle. J. Pharmacol. Exp. Ther. 356, 74–84.
49. Guo, F. C., Huang, C. H., Liao, X. L., Wang, Y. M., He, Y., et al. (2011) Beneficial effects of mangiferin on hyperlipidemia in high-fat-fed hamsters. Mol. Nutr. Food Res. 55, 1809–1818.
50. Niu, Y. C., Li, S. T., Na, L. X., Feng, R. N., Liu, L. Y., et al. (2012) mangiferin decreases plasma free fatty acids through promoting its catabolism in liver by activation of AMPK. Plos One 7, e30782.
51. Xing, X., Li, D., Chen, D., Zhou, L., Chonan, R., et al. (2014) Mangiferin treatment inhibits hepatic expression of acyl-coenzyme A: diacylglycerol acyltransferase-2 in fructose-fed spontaneously hypertensive rats: a link to amelioration of fatty liver. Toxicol. Appl. Pharmacol. 280, 207–215.
52. Na, L. X., Zhang, Q., Jiang, S., Du, S. S., Zhang, W., et al. (2015) Mangiferin supplementation improves serum lipid profiles in overweight patients with hyperlipidemia: a double-blind randomized controlled trial. Sci Rep. 5, 10344.
53. Mahali, S. K., and Manna, S. K. (2012) Beta-d-glucoside protects against advanced glycation end products (AGEs)-mediated diabetic responses by suppressing ERK and inducing PPAR gamma DNA binding. Biochem. Pharmacol. 84, 1681–1690.
54. Mahali, S. K., Verma, N., and Manna, S. K. (2014) Advanced glycation end products induce lipogenesis: regulation by natural xanthone through inhibition of ERK and NF-kappaB. J. Cell. Physiol. 229, 1972–1980.
55. Kaul, D., Anand, P. K., and Khanna, A. (2006) Functional genomics of PPAR-gamma in human immunomodulatory cells. Mol. Cell. Biochem. 290, 211–215.
56. Giron, M. D., Sevillano, N., Salto, R., Haidour, A., Manzano, M., et al. (2009) Salacia oblonga extract increases glucose transporter 4-mediated glucose uptake in L6 rat myotubes: role of mangiferin. Clin. Nutr. 28, 565–574.
57. Dudhia, Z., Louw, J., Muller, C., Joubert, E., de Beer, D., Kinnear, C., et al. (2013) Cyclopia maculata and Cyclopia subternata (honeybush tea) inhibits adipogenesis in 3T3-L1 pre-adipocytes. Phytomed. Int. J. Phytother. Phytopharmacol. 20, 401–408.
58. Wilkinson, A. S., Monteith, G. R., Shaw, P. N., Lin, C. N., Gidley, M. J., et al. (2008) Effects of the mango components mangiferin and quercetin and the putative mangiferin metabolite norathyriol on the transactivation of peroxisome proliferator-activated receptor isoforms. J. Agric. Food Chem. 56, 3037–3042.
59. Miura, T., Ichiki, H., Hashimoto, I., Iwamoto, N., Kato, M., et al. (2001) Antidiabetic activity of a xanthone compound, mangiferin. Phytomed. Int. J. Phytother. Phytopharmacol. 8, 85–87.
60. Miura, T., Iwamoto, N., Kato, M., Ichiki, H., Kubo, M., et al. (2001) Effect of mangiferin on muscle GLUT4 protein content in TSOD (Tsumura, Suzuki, Obese, Diabetes) mouse, a new type 2 diabetic mice. Biomed. Res. Tokyo 22, 249–252.
61. Sellamuthu, P. S., Muniappan, B. P., Perumal, S. M., and Kandasamy, M. (2009) Antihyperglycemic effect of mangiferin in streptozotocin induced diabetic rats. J. Health Sci. 55, 206–214.
62. Pal, P. B., Sinha, K., and Sil, P. C. (2014) Mangiferin attenuates diabetic nephropathy by inhibiting oxidative stress mediated signaling cascade, TNFalpha related and mitochondrial dependent apoptotic pathways in streptozotocin-induced diabetic rats. PloS One 9, e107220.
63. Li, Y., Peng, G., Li, Q., Wen, S., Huang, T. H., et al. (2004) Salacia oblonga improves cardiac fibrosis and inhibits postprandial hyperglycemia in obese Zucker rats. Life Sci. 75, 1735–1746.
64. Saleh, S., El-Maraghy, N., Reda, E., and Barakat, W. (2014) Modulation of diabetes and dyslipidemia in diabetic insulin-resistant rats by mangiferin: role of adiponectin and TNF-alpha. Anais da Academia Brasileira de Ciencias 86, 1935–1948.
65. Kumar, B. D., Krishnakumar, K., Jaganathan, S. K., and Mandal, M. (2013) Effect of mangiferin and mahanimbine on glucose utilization in 3T3-L1 cells. Pharmacogn. Mag. 9, 72–75.
66. Kim, M., Lee, J. S., Oh, J. E., Nan, J., Lee, H., et al. (2015) SIRT3 overexpression attenuates palmitate-induced pancreatic beta-cell dysfunction. PloS One 10, e0124744.
67. Yuan, L., Deng, X., Chen, L., and Zhou, M. (2004) Regulation of insulin secretion and expression of SUR1 gene by chronic exposure to free fatty acids in rat pancreatic beta cells. J. Huazhong Univ. Sci. Technol. Med. Sci. 24, 358–360, 364.
68. Elsner, M., Gehrmann, W., and Lenzen, S. (2011) Peroxisome-generated hydrogen peroxide as important mediator of lipotoxicity in insulin-producing cells. Diabetes 60, 200–208.
69. Muruganandan, S., Gupta, S., Kataria, M., Lal, J., and Gupta, P. K. (2002) Mangiferin protects the streptozotocin-induced oxidative damage to cardiac and renal tissues in rats. Toxicology 176, 165–173.
70. Sellamuthu, P. S., Arulselvan, P., Kamalraj, S., Fakurazi, S., and Kandasamy, M. (2013) Protective nature of mangiferin on oxidative stress and antioxidant status in tissues of streptozotocin-induced diabetic rats. ISRN Pharmacol. 2013, 750109.
71. Sellamuthu, P. S., Arulselvan, P., Muniappan, B. P., Fakurazi, S., and Kandasamy, M. (2013) Mangiferin from Salacia chinensis prevents oxidative stress and protects pancreatic beta-cells in streptozotocin-induced diabetic rats. J. Med. Food 16, 719–727.
72. Li, X. J., Du, Z. C., Huang, Y., Liu, B. M., Hu, W. J., et al. (2013) Synthesis and hypoglycemic activity of esterified-derivatives of mangiferin. Chinese J. Nat. Med. 11, 296–301.
73. Wang, H. L., Li, C. Y., Zhang, B., Liu, Y. D., Lu, B. M., et al. (2014) Mangiferin facilitates islet regeneration and beta-cell proliferation through upregulation of cell cycle and beta-cell regeneration regulators. Int. J. Mol. Sci. 15, 9016–9035.
74. Brownlee, M. (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813–820.
75. Li, X. A., Cui, X. B., Sun, X. Y., Li, X. D., Zhu, Q., et al. (2010) Mangiferin prevents diabetic nephropathy progression in streptozotocin-induced diabetic rats. Phytother. Res. 24, 893–899.
76. Liu, Y. W., Zhu, X., Zhang, L., Lu, Q., Wang, J. Y., et al. (2013) Up-regulation of glyoxalase 1 by mangiferin prevents diabetic nephropathy progression in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 721, 355–364.
77. Pal, P. B., Sinha, K., and Sil, P. C. (2013) Mangiferin, a natural xanthone, protects murine liver in Pb(II) induced hepatic damage and cell death via MAP kinase, NF-kappaB and mitochondria dependent pathways. PloS One 8, e56894.
78. He, L. Y., Peng, X. F., Zhu, J. F., Chen, X., Liu, H., et al. (2014) Mangiferin attenuate sepsis-induced acute kidney injury via antioxidant and anti-inflammatory effects. Am. J. Nephrol. 40, 441–450.
79. Zhu, X., Cheng, Y. Q., Du, L., Li, Y., Zhang, F., et al. (2015) Mangiferin attenuates renal fibrosis through down-regulation of osteopontin in diabetic rats. Phytother. Res. 29, 295–302.
80. Yang, H., Gao, L. H., Niu, Y. F., Zhou, Y. F., Lin, H., et al. (2015) Mangiferin inhibits renal urate reabsorption by modulating urate transporters in experimental hyperuricemia. Biol. Pharm. Bull. 38, 1591–1598.
81. Prabhu, S., Jainu, M., Sabitha, K. E., and Shyamala Devi, C. S. (2006) Effect of mangiferin on mitochondrial energy production in experimentally induced myocardial infarcted rats. Vasc. Pharmacol. 44, 519–525.
82. Hou, J., Zheng, D., Fung, G., Deng, H., Chen, L., et al. (2016) Mangiferin suppressed advanced glycation end products (AGEs) through NF-kappaB deactivation and displayed anti-inflammatory effects in streptozotocin and high fat diet–diabetic cardiomyopathy rats. Can. J. Physiol. Pharmacol. 94, 331–340.
83. Zhou, Y. T., Grayburn, P., Karim, A., Shimabukuro, M., Higa, M., et al. (2000) Lipotoxic heart disease in obese rats: implications for human obesity. Proc. Natl. Acad. Sci. USA 97, 1784–1789.
84. Huang, T. H., Yang, Q., Harada, M., Uberai, J., Radford, J., et al. (2006) Salacia oblonga root improves cardiac lipid metabolism in Zucker diabetic fatty rats: modulation of cardiac PPAR-alpha-mediated transcription of fatty acid metabolic genes. Toxicol. Appl. Pharmacol. 210, 78–85.
85. Finck, B. N., Lehman, J. J., Leone, T. C., Welch, M. J., Bennett, M. J., et al. (2002) The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J. Clin. Investig. 109, 121–130.
86. Huang, T. H., Peng, G., Li, G. Q., Yamahara, J., Roufogalis, B. D., et al. (2006) Salacia oblonga root improves postprandial hyperlipidemia and hepatic steatosis in Zucker diabetic fatty rats: activation of PPAR-alpha. Toxicol. Appl. Pharmacol. 210, 225–235.
87. Goran, M. I., Walker, R., and Allayee, H. (2012) Genetic-related and carbohydrate-related factors affecting liver fat accumulation. Curr. Opin. Clin. Nutr. Metab. Care 15, 392–396.
88. Kulavarasalingam, K., and Bhatnagar, D. (2014) Interaction between carbohydrates and lipid metabolism. Curr. Opin. Lipidol. 25, 401–402.
89. Spriet, L. L. (2014) New insights into the interaction of carbohydrate and fat metabolism during exercise. Sports Med. 44, 87–96.
90. Iwamoto, S., Boonvisut, S., Makishima, S., Ishizuka, Y., Watanabe, K., et al. (2015) The role of TRIB1 in lipid metabolism; from genetics to pathways. Biochem. Soc. Trans. 43, 1063–1068.
91. Yamagishi, S., Maeda, S., Matsui, T., Ueda, S., Fukami, K., et al. (2012) Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochim. Biophys. Acta 1820, 663–671.
92. Yamagishi, S., and Matsui, T. (2016) Pathologic role of dietary advanced glycation end products in cardiometabolic disorders, and therapeutic intervention. Nutrition 32, 157–165.
93. Mastrocola, R., Collino, M., Rogazzo, M., Medana, C., Nigro, D., et al. (2013) Advanced glycation end products promote hepatosteatosis by interfering with SCAP–SREBP pathway in fructose-drinking mice. Am. J. Physiol. Gastrointest. Liver Physiol. 305, G398–G407.
94. Mastrocola, R., Collino, M., Nigro, D., Chiazza, F., D'Antona, G., et al. (2015) Accumulation of advanced glycation end-products and activation of the SCAP/SREBP lipogenetic pathway occur in diet-induced obese mouse skeletal muscle. PloS One 10, e0119587.
95. Mastrocola, R., Nigro, D., Chiazza, F., Medana, C., Dal Bello, F., et al. (2015) Fructose-derived advanced glycation end-products drive lipogenesis and skeletal muscle reprogramming via SREBP-1c dysregulation in mice. Free Radic. Biol. Med. 91, 224–235.
96. Machann, J., Haring, H., Schick, F., and Stumvoll, M. (2004) Intramyocellular lipids and insulin resistance. Diabet. Obes. Metab. 6, 239–248.
97. Martins, A. R., Nachbar, R. T., Gorjao, R., Vinolo, M. A., Festuccia, W. T., et al. (2012) Mechanisms underlying skeletal muscle insulin resistance induced by fatty acids: importance of the mitochondrial function. Lipids Health Dis. 11, 30.
98. Shoelson, S. E., Lee, J., and Goldfine, A. B. (2006) Inflammation and insulin resistance. J. Clin. Investig. 116, 1793–1801.
99. de Luca, C., and Olefsky, J. M. (2008) Inflammation and insulin resistance. FEBS Lett. 582, 97–105.
100. Osborn, O., and Olefsky, J. M. (2012) The cellular and signaling networks linking the immune system and metabolism in disease. Nat. Med. 18, 363–374.
101. McArdle, M. A., Finucane, O. M., Connaughton, R. M., McMorrow, A. M., and Roche, H. M. (2013) Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies. Front. Endocrinol. 4, 52.
102. Pal, M., Febbraio, M. A., and Lancaster, G. I. (2016) The roles of c-Jun NH2-terminal kinases (JNKs) in obesity and insulin resistance. J. Physiol. 594, 267–279.
103. Petersen, K. F., Dufour, S., Befroy, D., Garcia, R., and Shulman, G. I. (2004) Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. New Engl. J. Med. 350, 664–671.
104. Leiro, J., Arranz, J. A., Yanez, M., Ubeira, F. M., Sanmartin, M. L., et al. (2004) Expression profiles of genes involved in the mouse nuclear factor-kappa B signal transduction pathway are modulated by mangiferin. Int. Immunopharmacol. 4, 763–778.
105. Tsubaki, M., Takeda, T., Kino, T., Itoh, T., Imano, M., et al. (2015) Mangiferin suppresses CIA by suppressing the expression of TNF-alpha, IL-6, IL-1 beta, and RANKL through inhibiting the activation of NF-kappa B and ERK1/2. Am. J. Transl. Res. 7, 1371–1381.
106. Wei, Z., Yan, L., Deng, J., and Deng, J. (2011) [Effects of mangiferin on MAPK signaling pathway in chronic inflammation]. Zhongguo Zhong yao za zhi 36, 1798–1802.
107. Dou, W., Zhang, J., Ren, G., Ding, L., Sun, A., Deng, C., Wu, X., Wei, X., Mani, S., and Wang, Z. (2014) Mangiferin attenuates the symptoms of dextran sulfate sodium-induced colitis in mice via NF-kappaB and MAPK signaling inactivation. Int. Immunopharmacol. 23, 170–178.
108. Wang, J., Nie, Y., Li, Y., Hou, Y., Zhao, W., et al. (2015) Identification of target proteins of mangiferin in mice with acute lung injury using functionalized magnetic microspheres based on click chemistry. J. Agric. Food Chem. 63, 10013–10021.
109. Sahoo, B. K., Zaidi, A. H., Gupta, P., Mokhamatam, R. B., Raviprakash, N., et al. (2015) A natural xanthone increases catalase activity but decreases NF-kappa B and lipid peroxidation in U-937 and HepG2 cell lines. Eur. J. Pharmacol. 764, 520–528.
110. Pan, C. W., Pan, Z. Z., Hu, J. J., Chen, W. L., Zhou, G. Y., et al. (2016) Mangiferin alleviates lipopolysaccharide and d-galactosamine-induced acute liver injury by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation. Eur. J. Pharmacol. 770, 85–91.
111. DiMauro, S., and Schon, E. A. (2003) Mechanisms of disease: mitochondrial respiratory-chain diseases. New Engl. J. Med. 348, 2656–2668.
112. Lowell, B. B. and Shulmanz, G. I. (2005) Mitochondrial dysfunction and type 2 diabetes. Science 307, 384–387.
113. Wallace, D. C. (2005) A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu. Rev. Genet. 39, 359–407.
114. Chance, B., Sies, H., and Boveris, A. (1979) Hydroperoxide metabolism in mammalian organs. Physiol. Rev. 59, 527–605.
115. Balaban, R. S., Nemoto, S., and Finkel, T. (2005) Mitochondria, oxidants, and aging. Cell 120, 483–495.
116. Murphy, M. P. (2009) How mitochondria produce reactive oxygen species. Biochem. J. 417, 1–13.
117. Baynes, J. W., and Thorpe, S. R. (1999) Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48, 1–9.
118. Ceriello, A. (2000) Oxidative stress and glycemic regulation. Metab. Clin. Exp. 49, 27–29.
119. Wattanapitayakul, S. K., and Bauer, J. A. (2001) Oxidative pathways in cardiovascular disease—roles, mechanisms, and therapeutic implications. Pharmacol. Ther. 89, 187–206.
120. Maritim, A. C., Sanders, R. A., and Watkins, J. B., 3rd. (2003) Diabetes, oxidative stress, and antioxidants: a review. J. Biochem. Mol. Toxicol. 17, 24–38.
121. Drummond, G. R., Selemidis, S., Griendling, K. K., and Sobey, C. G. (2011) Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat. Rev. Drug. Discov. 10, 453–471.
122. Rajendran, P., Rengarajan, T., Nandakumar, N., Divya, H., and Nishigaki, I. (2015) Mangiferin in cancer chemoprevention and treatment: pharmacokinetics and molecular targets. J. Receptor Signal Trans. Res. 35, 76–84.